The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the space that’s about to go clinical!”.
Broad Media Coverage of the launch of Sound Bioventures Fund I
A visionary journey to innovate sight-preserving therapies
Breye Therapeutics is all about the people. Whether it’s the company’s team or the patients whose eyesight they seek to protect, the focus is consistently on the human factor. It’s a value influenced by CEO and founder Ulrik Mouritzen, whose career in drug development has taught him the importance of collaboration in delivering life-changing therap ...
Maximizing positive impacts with an entrepreneurial mindset
Thomas Tan knows the founder’s journey inside and out. The scientist-turned-entrepreneur has lived it, as well as logged countless hours as a lab researcher and a management consultant. That wealth of experience is a major part of what informs Tan’s approach to his role as Principal at Sound Bioventures. Early on, Tan saw two paths […] ...
A dedication to solving unmet medical needs through collaboration
Johan Kördel can trace his decision to co-found Sound Bioventures to a conversation back in 2018. After spending the better part of a decade as senior partner at a venture capital fund, leading investments and serving on many companies’ boards of directors, Kördel felt an increasing need to do something different. He was telling a […]
New members to the team
Today it was announced that Philip Brainin and Anne Marie Simon have joined the Sound Bioventures team.